Merck Sharp and Dohme to present Keytruda data at upcoming conferences

Merck Sharp and Dohme will be presenting the first data on its new anti-PD-1 therapy Keytruda at medical conferences taking place during November and December 2014.

The company will attend the Society for Melanoma Research's 2014 International Congress this week, as well as December's American Society of Hematology annual meeting and the San Antonio Breast Cancer Symposium, in order to share these insights.

Keytruda has been evaluated in advanced melanoma in comparison to chemotherapy, as well as in relapsed/refractory classical Hodgkin lymphoma and advanced triple-negative breast cancer.

Positive data from these studies will help to support the company's application for regulatory approval of the drug.

Dr Roy Baynes, senior vice-president for global clinical development at Merck Research Laboratories, said: "We continue to expand our immuno-oncology clinical programme with Keytruda both as monotherapy and in combination with other agents."

The company is attending the American Association for the Study of Liver Diseases this week, where it is sharing its latest hepatitis C drug research findings.